{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:03:48Z","timestamp":1768986228245,"version":"3.49.0"},"reference-count":51,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM112666"],"award-info":[{"award-number":["R01 GM112666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The proteolytic processing of the SARS-CoV-2 spike glycoprotein by host cell membrane-associated proteases is a key step in both the entry of the invading virus into the cell and the release of the newly generated viral particles from the infected cell. Because of the critical importance of this step for the viral infectivity cycle, it has been a target of extensive efforts aimed at identifying highly specific protease inhibitors as potential antiviral agents. An alternative strategy to disrupt the pre-fusioviden processing of the SARS-CoV-2 S glycoprotein aims to protect the substrate rather than directly inhibit the proteases. In this work, we focused on furin, a serine protease located primarily in the Golgi apparatus, but also present on the cell membrane. Its cleavage site within the S glycoprotein is located within the stalk region of the latter and comprises an arginine-rich segment (SPRRARS), which fits the definition of the Cardin\u2013Weintraub glycosaminoglycan recognition motif. Native mass spectrometry (MS) measurements confirmed the binding of a hexadecameric peptide representing the loop region at the S1\/S2 interface and incorporating the furin cleavage site (FCS) to heparin fragments of various lengths, as well as unfractionated heparin (UFH), although at the physiological ionic strength, only UFH remains tightly bound to the FCS. The direct LC\/MS monitoring of FCS digestion with furin revealed a significant impact of both heparin fragments and UFH on the proteolysis kinetics, although only the latter had IC50 values that could be considered physiologically relevant (0.6 \u00b1 0.1 mg\/mL). The results of this work highlight the importance of the long-range and relatively non-specific electrostatic interactions in modulating physiological and pathological processes and emphasize the multi-faceted role played by heparin in managing coronavirus infections.<\/jats:p>","DOI":"10.3390\/biom15060778","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:46:38Z","timestamp":1748493998000},"page":"778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Long-Range Non-Specific Electrostatic Interactions in Inhibiting the Pre-Fusion Proteolytic Processing of the SARS-CoV-2 S Glycoprotein by Heparin"],"prefix":"10.3390","volume":"15","author":[{"given":"Yi","family":"Du","sequence":"first","affiliation":[{"name":"Department of Chemistry, University of Massachusetts-Amherst, Amherst, MA 01003, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Massachusetts-Amherst, Amherst, MA 01003, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-1685","authenticated-orcid":false,"given":"Son N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Massachusetts-Amherst, Amherst, MA 01003, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-6039","authenticated-orcid":false,"given":"Igor A.","family":"Kaltashov","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Massachusetts-Amherst, Amherst, MA 01003, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Carvajal, J.J., Garc\u00eda-Castillo, V., Cuellar, S.V., Campillay-V\u00e9liz, C.P., Salazar-Ardiles, C., Avellaneda, A.M., Mu\u00f1oz, C.A., Retamal-D\u00edaz, A., Bueno, S.M., and Gonz\u00e1lez, P.A. (2024). New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1363572"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maison, D.P., Tasissa, H., Deitchman, A., Peluso, M.J., Deng, Y., Miller, F.D., Henrich, T.J., and Gerschenson, M. (2025). COVID-19 clinical presentation, management, and epidemiology: A concise compendium. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1498445"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3201\/eid1003.030683","article-title":"Coronaviridae and SARS-associated coronavirus strain HSR1","volume":"10","author":"Vicenzi","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/rth2.12353","article-title":"Using heparin molecules to manage COVID-2019","volume":"4","author":"Liu","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities","volume":"319","author":"Hippensteel","year":"2020","journal-title":"Am. J. Physiol. Lung. Cell. Mol. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1076029620938149","DOI":"10.1177\/1076029620938149","article-title":"COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation","volume":"26","author":"Miesbach","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/jth.14898","article-title":"Heparin\u2014An old drug with multiple potential targets in COVID-19 therapy","volume":"18","author":"Lindahl","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin","volume":"120","author":"Su","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10930","DOI":"10.1021\/acs.analchem.0c02449","article-title":"The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: Heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor","volume":"92","author":"Yang","year":"2020","journal-title":"Anal. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1007\/s00216-021-03601-3","article-title":"The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor","volume":"413","author":"Yang","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104873","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.ATV.9.1.21","article-title":"Molecular modeling of protein-glycosaminoglycan interactions","volume":"9","author":"Cardin","year":"1989","journal-title":"Arteriosclerosis"},{"key":"ref_15","first-page":"162","article-title":"SARS-CoV-2 variant biology: Immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Barile, E., Baggio, C., Gambini, L., Shiryaev, S.A., Strongin, A.Y., and Pellecchia, M. (2020). Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming. Molecules, 25.","DOI":"10.3390\/molecules25102424"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ivachtchenko, A.V., Khvat, A.V., and Shkil, D.O. (2024). Development and Prospects of Furin Inhibitors for Therapeutic Applications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179199"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sasaki, M., Toba, S., Itakura, Y., Chambaro, H.M., Kishimoto, M., Tabata, K., Intaruck, K., Uemura, K., Sanaki, T., and Sato, A. (2021). SARS-CoV-2 Bearing a Mutation at the S1\/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. mBio, 12.","DOI":"10.1128\/mBio.01415-21"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16396","DOI":"10.1016\/S0021-9258(18)42016-9","article-title":"Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen","volume":"267","author":"Molloy","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","article-title":"OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules","volume":"15","author":"Roos","year":"2019","journal-title":"J. Chem. Theory. Comput."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/prot.10532","article-title":"Predicting intrinsic disorder from amino acid sequence","volume":"53","author":"Obradovic","year":"2003","journal-title":"Proteins"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/anie.200300640","article-title":"A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?","volume":"43","author":"Petitou","year":"2004","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1021\/bm1008074","article-title":"Protein Specificity of Charged Sequences in Polyanions and Heparins","volume":"11","author":"Kayitmazer","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1021\/acs.analchem.0c00115","article-title":"Identification of Protein Recognition Elements within Heparin Chains Using Enzymatic Foot-Printing in Solution and Online SEC\/MS","volume":"92","author":"Niu","year":"2020","journal-title":"Anal. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jms.723","article-title":"On-line size-exclusion chromatography\/mass spectrometry of low molecular mass heparin","volume":"39","author":"Henriksen","year":"2004","journal-title":"J. Mass Spectrom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1021\/ac101848z","article-title":"Electrospray ionization mass spectrometry of highly heterogeneous protein systems: Protein ion charge state assignment via incomplete charge reduction","volume":"82","author":"Abzalimov","year":"2010","journal-title":"Anal. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1021\/acs.analchem.5b03792","article-title":"Interactions of Intact Unfractionated Heparin with Its Client Proteins Can Be Probed Directly Using Native Electrospray Ionization Mass Spectrometry","volume":"88","author":"Zhao","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yang, Y., Du, Y., Ivanov, D., Niu, C., Clare, R., Smith, J.W., Nazy, I., and Kaltashov, I.A. (2024). Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-05982-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/pr8009879","article-title":"18O2-Labeling in quantitative proteomic strategies: A status report","volume":"8","author":"Fenselau","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of Heparin and Related Drugs: An Update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.chest.2022.01.036","article-title":"POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients with COVID-19? Yes","volume":"161","author":"Tritschler","year":"2022","journal-title":"Chest"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.18087\/cardio.2024.5.n2186","article-title":"Heparin-Induced Thrombocytopenia","volume":"64","author":"Sugraliyev","year":"2024","journal-title":"Kardiologiia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/ijlh.13582","article-title":"The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19","volume":"43","author":"Favaloro","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1042\/bj3220499","article-title":"Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species","volume":"322","author":"Toida","year":"1997","journal-title":"Biochem. J."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Paiardi, G., Richter, S., Oreste, P., Urbinati, C., Rusnati, M., and Wade, R.C. (2022). The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2021.101507"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00249-003-0316-9","article-title":"Conformation of heparin studied with macromolecular hydrodynamic methods and X-ray scattering","volume":"32","author":"Pavlov","year":"2003","journal-title":"Eur. Biophys. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eade5085","DOI":"10.1126\/sciadv.ade5085","article-title":"The D614G mutation redirects SARS-CoV-2 spike to lysosomes and suppresses deleterious traits of the furin cleavage site insertion mutation","volume":"8","author":"Guo","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1074\/jbc.M109.037358","article-title":"Heparin enhances serpin inhibition of the cysteine protease cathepsin L","volume":"285","author":"Higgins","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e77444","DOI":"10.7554\/eLife.77444","article-title":"Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry","volume":"11","author":"Kastenhuber","year":"2022","journal-title":"eLife"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0140-6736(22)01585-9","article-title":"The Lancet Commission on lessons for the future from the COVID-19 pandemic","volume":"400","author":"Sachs","year":"2022","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/23744235.2025.2452862","article-title":"Long-term health outcomes following hospitalisation for COVID-19: A 30- month cohort analysis","volume":"57","author":"Tubiana","year":"2025","journal-title":"Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lee, L.Y.Y., Suryadinata, R., McCafferty, C., Ignjatovic, V., Purcell, D.F.J., Robinson, P., Morton, C.J., Parker, M.W., Anderson, G.P., and Monagle, P. (2022). Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells. Viruses, 14.","DOI":"10.3390\/v14122620"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:41:49Z","timestamp":1760031709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biom15060778"],"URL":"https:\/\/doi.org\/10.3390\/biom15060778","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}